Johnson & Johnson (JNJ)
144.77
+0.32
(+0.22%)
USD |
NYSE |
Apr 17, 16:00
144.69
-0.08
(-0.06%)
Pre-Market: 20:00
Johnson & Johnson Revenue (TTM): 93.02B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 93.02B |
| September 30, 2023 | 91.57B |
| June 30, 2023 | 90.21B |
| March 31, 2023 | 88.70B |
| December 31, 2022 | 87.38B |
| September 30, 2022 | 77.21B |
| June 30, 2022 | 80.55B |
| March 31, 2022 | 79.84B |
| December 31, 2021 | 78.74B |
| September 30, 2021 | 91.45B |
| June 30, 2021 | 89.19B |
| March 31, 2021 | 84.21B |
| December 31, 2020 | 82.58B |
| September 30, 2020 | 80.86B |
| June 30, 2020 | 80.50B |
| March 31, 2020 | 82.73B |
| December 31, 2019 | 82.06B |
| September 30, 2019 | 81.71B |
| June 30, 2019 | 81.32B |
| March 31, 2019 | 81.59B |
| December 31, 2018 | 81.58B |
| September 30, 2018 | 81.38B |
| June 30, 2018 | 80.68B |
| March 31, 2018 | 78.69B |
| December 31, 2017 | 76.45B |
| Date | Value |
|---|---|
| September 30, 2017 | 74.36B |
| June 30, 2017 | 72.53B |
| March 31, 2017 | 72.17B |
| December 31, 2016 | 71.89B |
| September 30, 2016 | 71.60B |
| June 30, 2016 | 70.88B |
| March 31, 2016 | 70.18B |
| December 31, 2015 | 70.07B |
| September 30, 2015 | 70.52B |
| June 30, 2015 | 71.88B |
| March 31, 2015 | 73.59B |
| December 31, 2014 | 74.33B |
| September 30, 2014 | 74.43B |
| June 30, 2014 | 73.54B |
| March 31, 2014 | 71.92B |
| December 31, 2013 | 71.31B |
| September 30, 2013 | 70.52B |
| June 30, 2013 | 69.99B |
| March 31, 2013 | 68.59B |
| December 31, 2012 | 67.22B |
| September 30, 2012 | 65.92B |
| June 30, 2012 | 64.87B |
| March 31, 2012 | 65.00B |
| December 31, 2011 | 65.03B |
| September 30, 2011 | 64.42B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
77.21B
Minimum
Sep 2022
93.02B
Maximum
Dec 2023
84.41B
Average
82.58B
Median
Dec 2020
Revenue (TTM) Benchmarks
| Amgen Inc | 28.19B |
| Gilead Sciences Inc | 27.12B |
| Eli Lilly and Co | 34.12B |
| Merck & Co Inc | 60.11B |
| Shockwave Medical Inc | 730.23M |